In a note released Monday morning Jefferies analyst David Steinberg initiated coverage on Amphastar Pharmaceuticals AMPH with a Buy rating and a $14 price target.
Steinberg wrote, "Unlike most of its competitors, Amphastar has the skills and technology to successfully tackle some of the most challenging generic opportunities - particularly those in the high value injectable and inhalation niches."
Steinberg noted that Amphastar is able to differentiate itself from "traditional" generic drug companies through its vertical integration and "heavy" investment in R&D, a feature he said has positioned the company "very well" in generic injectables and inhalation markets.
Despite the Jefferies note, shares of Amphastar are trading over four percent lower.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.